Clinical Trial Update: Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) [Phase 3]

View source ↗

Summary

Phase 3 study update for ozanimod (RPC1063) in relapsing multiple sclerosis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ozanimod (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-11-25